-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On the occasion of ASCO 2021, the annual event of clinical oncology, NEJM Medical Frontier invited Dr.
Dan Longo, the editor in charge of the New England Journal of Medicine (NEJM), to summarize the progress of tumor immunotherapy in the past three years and clarify the main lines and trends of frontier progress.
Play the first part today.
The speaker introduced that Dr.
Longo is currently the Deputy Editor of NEJM, responsible for reviews and manuscripts in the field of oncology.
Professor of Harvard Medical School and concurrently a senior physician at Brigham and Women's Hospital.
Member of the American Association for the Advancement of Science (AAAS).
He is also the editor of Harrison's Principles of Internal Medicine.
He has published more than 980 papers and monograph chapters, and is the author of the top 1% global citation rate in the field of life sciences.
Dr.
Longo's scientific research interests focus on the mechanisms of tumor suppression of T cells and other fields.
He has developed multiple therapies that have improved the survival of patients with tumors such as lymphoma.
What elements are required for excellent clinical research in the classroom as the editor-in-chief of NEJM? Can negative results be published in high-impact journals? What types of clinical research does the New England Journal of Medicine favor? What are the characteristics of clinical research in various specialties, and what are the cutting-edge developments? We will successively launch clinical research and paper publishing courses led by the editors of the New England Journal of Medicine (NEJM).
Related reading NEJM Editor-in-Chief Classroom: Excellent Clinical Research from the Perspective of NEJM (Part 1) NEJM Editor-in-Chief Classroom: Excellent Clinical Research from the Perspective of NEJM (Part 2) Copyright information Translation, writing or commissioning of the "NEJM Frontiers in Medicine" jointly created by the Journal of Medicine (NEJM).
The Chinese translation of the full text and the included diagrams are exclusively authorized by the NEJM Group.
If you need to reprint, please leave a message or contact nejmqianyan@nejmqianyan.
cn.
Unauthorized translation is an infringement, and the copyright owner reserves the right to pursue legal liabilities.
Dan Longo, the editor in charge of the New England Journal of Medicine (NEJM), to summarize the progress of tumor immunotherapy in the past three years and clarify the main lines and trends of frontier progress.
Play the first part today.
The speaker introduced that Dr.
Longo is currently the Deputy Editor of NEJM, responsible for reviews and manuscripts in the field of oncology.
Professor of Harvard Medical School and concurrently a senior physician at Brigham and Women's Hospital.
Member of the American Association for the Advancement of Science (AAAS).
He is also the editor of Harrison's Principles of Internal Medicine.
He has published more than 980 papers and monograph chapters, and is the author of the top 1% global citation rate in the field of life sciences.
Dr.
Longo's scientific research interests focus on the mechanisms of tumor suppression of T cells and other fields.
He has developed multiple therapies that have improved the survival of patients with tumors such as lymphoma.
What elements are required for excellent clinical research in the classroom as the editor-in-chief of NEJM? Can negative results be published in high-impact journals? What types of clinical research does the New England Journal of Medicine favor? What are the characteristics of clinical research in various specialties, and what are the cutting-edge developments? We will successively launch clinical research and paper publishing courses led by the editors of the New England Journal of Medicine (NEJM).
Related reading NEJM Editor-in-Chief Classroom: Excellent Clinical Research from the Perspective of NEJM (Part 1) NEJM Editor-in-Chief Classroom: Excellent Clinical Research from the Perspective of NEJM (Part 2) Copyright information Translation, writing or commissioning of the "NEJM Frontiers in Medicine" jointly created by the Journal of Medicine (NEJM).
The Chinese translation of the full text and the included diagrams are exclusively authorized by the NEJM Group.
If you need to reprint, please leave a message or contact nejmqianyan@nejmqianyan.
cn.
Unauthorized translation is an infringement, and the copyright owner reserves the right to pursue legal liabilities.
